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Superagonistic behaviour of epidermal growth factor/transforming growth 
factor-a chimaeras: correlation with receptor routing after ligand-induced 
internalization
Anne E. G. LENFERINK1, Roelof H. KRAMER, Marianne J. H. van VUGT, Monika KÖNIGSWIESER, Pier Paolo Dl FIORE*, 
Everardus J. J. van ZOELEN and Monique L. M. van de POLL
Department of Cell Biology, University of Nijmegen, Toernooiveld 1 ,  6525 E D  Nijmegen, The Netherlands, and "European Institute of Oncology, Milan, Italy
Human epidermal growth factor (EGF) and human transforming 
growth factor alpha (TGF-a) are structurally related polypeptide 
growth factors that exert their mitogenic activity through in­
teraction with a common cell-surface receptor, the epidermal 
growth factor receptor (EGFR). The biological effect induced by 
these two ligands is quantitatively similar in most cases; in some 
test systems, however, TGF-a functions as a more potent form of 
EGF. In this study, we have compared EGF, TGF-a and ten 
previously described chimaeras of these two ligands in terms of 
their ability to generate a mitogenic response in cells carrying the 
human EGFR, and observed that three of the mutant growth 
factors (E3T, E4T and T3E4T) are mitogenic at concentrations 
10-fold lower than that of either wild-type EGF or TGF-a. No 
difference in tyrosine kinase activity of the receptor towards an 
external substrate was observed after binding of the various
mutants. It has been established before [Ebner and Derynck 
(1991) Cell Regulation 2, 599-612] that EGF and TGF-a differ 
in the processing of the receptor-ligand complex after internali­
zation, as a result of their different pH sensitivities of receptor 
binding. Similar measurements on our chimaeric mutants re­
vealed that the above superagonists show an enhanced pH 
dependence of binding in comparison with EGF. Furthermore, 
induction of receptor recycling by these superagonists is largely 
comparable with that induced by TGF-a. No superagonistic 
behaviour was observed on a cell-line containing an EGFR/erbB-
2 chimaera which does not show ligand-induced internalization. 
These data show that EGF/TGFa chimaeras can be more active 
than the naturally occurring ligands, and that receptor recycling 
after ligand-induced internalization seems to be a prerequisite for 
this phenomenon.
IN T R O D U C T IO N
Human epidermal growth factor (EGF) and human transforming 
growth factor alpha (TGF-a) are members of a large family of 
structurally related polypeptide growth factors that exert their 
biological activity by binding to the EGF receptor (EGFR) [1]. 
Within both growth factors, six almost identically spaced 
cysteines form three disulphide bridges that are known to be 
essential for biological activity [2]. Binding of the ligand to the 
extracellular domain of the EGFR causes receptor dimerization, 
coupled to activation of the intrinsic tyrosine kinase activity. 
Although EGF and TGF-a bind with a very similar affinity to 
their receptor [3,4], several reports have described that TGF-a 
appears to be more potent than EGF in a variety of biological 
systems [5,6]. It has been established that EGF and TGF-a 
induce a different intracellular routing of the receptor after 
ligand-induced internalization [7]. Since EGF is a more acidic 
molecule than TGF-a, it remains bound to the EGFR after 
internalization during the gradual acidification of the endocytotic 
vesicles [8], finally resulting in proteolytic degradation of both 
ligand and receptor in the lysosomes. In contrast, TGF-a rapidly 
dissociates from the receptor after internalization, resulting in 
the recycling of both receptor and ligand to the cell surface. 
However, in most cell systems, this difference in receptor routing 
does not appear to affect the mitogenic potential of these growth 
factors.
Lax et al. [9] have shown that although EGF and TGF-a may 
have similar affinity for the human EGFR, EGF has a 100-fold 
lower affinity than TGF-a for the chicken EGFR. Recently, we 
have made ten EG F/TG F-a chimaeras on the basis of exchange
of domains within EGF and TGF-a that are bordered by their 
conserved cysteine residues. Using this approach, we concluded 
that the C-terminal domain of EGF is responsible for the low- 
affinity binding to the chicken EGFR [10]. In later studies, we 
have shown that replacement of Arg-45 in human EGF by the 
corresponding Ala of TGF-a is sufficient .to induce high-affinity 
binding to the chicken EGFR [11], indicating that this residue 
may be directly involved in receptor binding.
In the present study we have measured the mitogenic capacity 
of the above EGF/TGF-a chimaeras towards cells expressing 
the human EGFR. The present data show that three mutants, 
designated E3T, E4T and T3E4T, induce mitogenic activity at a 
10-fold lower concentration than wild-type human EGF and 
TGF-a, in spite of the fact that they have similar receptor- 
binding affinity and induce the same amount of EGFR tyrosine 
kinase activity. These three superagonists induce receptor re­
cycling after ligand-induced internalization, similar to TGF-a, 
and have an enhanced pH dependence of binding when compared 
with EGF. These data are interpreted in terms of the role of EGF 
receptor recycling in mitogenic activation by EGF-like growth 
factors.
M A T E R IA L S  A N D  M E T H O D S  
Expression and purification of recombinant growth factors
The DNA constructs for the expression of human EGF, TGF-a 
and EGF/TGF-a chimaeras were cloned into the pEZZ18 
expression vector (Pharmacia, Uppsala, Sweden), as described
[11], Wild-type and chimaeric growth factors were expressed and
Abbreviations used: DMEM, Dulbecco’s modified Eagle's medium; EGF(R), epidermal growth factor (receptor); FCS, foetal calf serum; IEP, isoelectric 
point; NCS, newborn calf serum; TdR, thymidine; TGF-a, transforming growth factor-a.
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secreted as protein A-/factor X-growth factor fusion proteins adjusted to different pHs using either NaOH or HC1. The
[12] into the periplasmic space of Escherichia coli strain KS474, 
a degP-pro tease-deficient mutant (a generous gift from Drs. 
K. L. Strauch and J. Beckwith, Harvard University; see also
[13]). The bacteria were grown in 2YTE medium [per litre: 16 g 
bactotryptone/10 g yeast extract/8 g NaCl/0.4%  (w/v) glucose] 
at 30 °C while agitating (200 rpm) until an A 600 of 1.5 was 
reached. The fusion proteins obtained were purified using IgG- 
Sepharose chromatography (Pharmacia, Uppsala, Sweden) and 
the recovery of the chimaeras was measured by an ELISA based 
on competitive binding with biotiii-labelled protein A [14]. The 
recombinant growth factors were enzymically separated from the 
protein A sequence by factor X digestion, after which the wild- 
type and mutant growth factors were purified by an additional 
run on an IgG-Sepharose column. Both dimeric and inactive 
forms with disulphide bridge mismatches were removed by 
reverse-phase I-IPLC on a Deltapak C l8 column (Waters Co­
operation, Milford, MA, USA) at a flow rate of 1 ml/min., using 
a linear gradient of 0-60%  acetonitrile in 0.1 % (v/v) triflu oro- 
acetate, as described previously [11]. Fractions (1 ml) were tested 
for EGFR-binding activity on HER-7 or H ER -14 cells (see 
below), and the amount of growth factor present was deduced 
from the peak area at 229 nm in the HPLC chromatogram, using 
natural murine EGF under the same experimental conditions as 
the standard [11].
recombinant wild-type and mutant growth factors were tested at 
a fixed concentration of 100 ng/ml.
Mitogenic Assays
HER-7, H ER-14 or HER-56 cells were seeded in gelatinized 24- 
well dishes (1.8 cm2) at a density of 6.0 x 104 cells/well in 1 ml 
DM EM /10%  (v/v) NCS. After 24 h incubation, the medium 
was replaced by 0.9 ml of D M EM /H am ’s F12 medium (Gibco- 
BRL) (1:1) supplemented with 30 nM Na2Se03, 10 /¿g/ml human 
transferrin and 0.5 % (w/v) BSA [DFST/o‘5 % (w/v) BSA]. 
After an additional 48 h, serial dilutions of recombinant growth 
factors were added in 0.1 ml DMEM/Bes (pH 6.8) and after a 
further 8 h, 0.5 //,Ci [3H]thymidine (TdR) was subsequently added 
in 0.1 ml Ham’s F I2 medium. Incorporation of the tracer into 
the cellular DNA was determined 24 h after growth factor 
addition as described previously [19].
HaCaT cells were seeded at a density of 3.0 x 10* cells/well in 
1 ml DM EM /10%  (v/v) FCS and grown for 3 days to 50% 
confluency. The medium was then replaced by 0.9 ml DFST/ 
0.5 % BSA and 24 h later serial dilutions of recombinant growth 
factors were added in 0.1 ml DMEM/Bes (pH 6.8) supplemented 
with 0.1% BSA. [3H]TdR incorporation was determined 24 h 
after growth factor addition as described above.
Cell culture
NIH-3T3 cells transfected with the wild-type human EGFR 
(HER-7 cells, 6.0 xIO5 human EG FR /cell; or HER-14 cells, 
4.0 x 105 human EGFR/cell; see [15]) were kindly provided by 
Dr. J. Schlessinger (New York University, NY). HaCaT, a 
human keratinocyte cell-line expressing the wild-type human 
EGFR, was a generous gift from Dr. N. E. Fusenig (Deutsches 
KrebsforschungsZentrum, Heidelberg, Germany; see[16]). NIH- 
3T3 fibroblasts transfected with a human EGFR/erbB-2 chim­
aera containing the human EGFR extracellular domain and the 
transmembrane and cytoplasmic domains of erbB-2 (HER-56 
cells, 1.0 x 10“ receptors/cell) were used as described by Sorkin et 
al. [17]. All cells were cultured in gelatinized flasks; HER-7, 
HER-14 and HER-56 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (w/v) new­
born calf serum (NCS), HaCaT cells were cultured in DMEM 
supplemented with 10% (w/v) foetal calf serum (FCS).
Murine 1ZBI-EG F-b in d in g  competition assays
Murine EGF (Bioproducts for Science Inc., Indianapolis, IN) 
was iodinated using enzymobeads (Bio-Rad) to a specific activity
of approx. 500 Ci/mmol [18]. HER-7, HER-14, HER-56 and
HaCaT cells were grown to conHuency in gelatinized 24-well 
dishes (1.8 cm2). The medium was removed and serial dilutions 
of wild-type orchimaeric growth factors were added to the cells 
in 100 ¡i\ DMEM containing 15 mM Hepes, pH 7.7 and supple­
mented with 10% NCS (DMEM/Hepes) together with 0.1 ng/ 
well murine 12r,I-EGF. After incubation for 2 h at room tem­
perature, the cells were rinsed twice with ice-cold PBS supple­
mented with 0.1 % (w/v) BSA and once with ice-cold PBS. Cells
Ligand-induced internalization of the human E G F R
HER-7 or HER-56 cells were grown to confluency in gelatinized 
24-well dishes. Subsequently the medium was replaced by 400 //I 
DFST medium and the recombinant chimaeric proteins were 
added to the cells in 100 //I DMEM/Bes (pH 6.8) to a final 
concentration of 100 ng/ml, with or without 0.3 mM monensin 
(Sigma, St. Louis, MO) and incubated for 1 h at 4 °C. Then the 
cells were incubated at 37 °C for the indicated time periods (see 
Results section), after which all non-internalized receptor-bound 
ligand was removed by an ice-cold acid wash (5 mM HOAc, 
135 mM NaCl, 2.5 mM KC1, pH 2.5). The cell medium was 
neutralized by rinsing twice with DM EM /10%  (v/v) NCS and 
incubation was continued for 1 h at 37 °C with 1 ml of the same 
medium, to allow any internalized intact receptors 
the cell surface.
To quantify the number of human EGFR present on the cell 
surface after down-regulation by the various recombinant growth 
factors, a murine 125I-EGF binding experiment was performed 
for 1 h at 4 °C.
Stimulation of receptor tyrosine kinase
The growth-factor-dependcnt tyrosine kinase activity of the 
human EGFR was determined by measuring the incorporation 
of [y-32P] ATP (1CN Biomedicals Inc., Costa Mesa, CA) into the 
synthetic polypeptide substrate angiotensin I (Sigma, St. Louis, 
MO). Membranes from HER-7 cells were isolated according to 
the method of Thom et al. [20] and preincubated for 60 min at 
room temperature with increasing concentrations of growth 
factors in 20 /d PBS/0.1 % (w/v) BSA. The tyrosine kinase 
reaction was initiated by the addition of 20 /d of ‘ 2 x ;i2P-assay
were then lysed by incubation with 250 //1/well 1 % (v/v) Triton mix ’ containing 40 mM Hepes (pH 7.4), 4 mM M nCL 20 mM p-
X-100 for 1 h at room temperature. Finally radioactivity present 
in the cell lysates was measured by y-counting.
The pH dependence of binding of the various chimaeric 
growth factors to the human EGFR was determined essentially 
as described above, except that the growth factors were now 
added in DMEM buffered with 50 mM Bes and supplemented 
with 0.1 % (w/v) BSA (DMEM/Bes) and the medium was
nitrophenyl phosphate, 80 /¿M Na,,V04, 30 /tM ATP, 0.4% 
(w/v) Nonidet P-40, 4 mM angiotensin I and 1 /¿Ci [y-3!!P]ATP. 
The mixture was incubated for 3 min at 30 °C, after which the
reaction was terminated by the addition of 50 //I 5 00 (v/v)
trichloroacetic acid and 2 0 //.l of 2.5% (w/v) BSA. Aliquots of 
20 /d of acid-soluble material were spotted onto phosphocellulose 
paper (Whatman P81). The filters were washed six times with
Superagonistic behaviour of growth factor chimaeras 861
7.5 mM phosphoric acid and subsequently dried. The radio- significantly higher than those observed for EGF and these 
activity incorporated into the peptide substrate was measured by superagonists, 
liquid scintillation counting.
R E S U L T S  
Mitogenic response of E G F / T G F - a  chimaeras towards human 
E G F R
Human EGF, human TGF-a and the chimaeric proteins were 
expressed in E. coli and purified by reverse-phase HPLC, as 
described [11]. The absorbance at 229 nm of the active peak was 
taken as a measure of the amount of growth factor present. All 
mutants tested showed, to within a factor of 2, a similar receptor- 
binding affinity to the human EGFR as murine EGF from a 
natural source, in agreement with data of van de Poll et al, [11]. 
Nomenclature used for the E G F/T G F-a chimaeras was similar 
to that used before [10]; e.g. E3T stands for a growth factor with 
EGF sequences N-terminal of and TGF-a sequences C-terminal 
of the third cysteine.
Figure 1(A) shows that EGF, TGF-a and most of the 
chimaeras tested have similar mitogenic activity towards HER-
14 cells. However, three chimaeras, designated as E3T, E4T and 
T3E4T, already show a mitogenic response at at least 10-fold 
lower concentrations, in spite of the fact that their receptor- 
binding affinity is similar to that of the other growth factors 
tested. Similar results were obtained on HER-7 cells, although 
the extent of growth stimulation was less than on the HER-14 
cells, due to the partly transformed character of these cells.
To be certain that this superagonistic response is not an 
artefact related to the particular cell lines used in these studies, a 
similar experiment was performed on a non-transformed human 
keratinocyte cell line (HaCaT) carrying endogenous human 
EGFRs. Figure 1(B) shows that in this cell-line also dose- 
response curves for mitogenic activity by the above superagonists 
are shifted to significantly lower concentrations. For reasons
E G F  receptor-induced tyrosine phosphorylation
The observation that E3T, E4T and T3E4T are capable of 
inducing a superagonistic response prompted us to evaluate the 
possibility that these ligands are able to convert the EGFR into 
a more active conformation. Therefore some of the ligands were 
tested for their ability to induce dose-dependent tyrosine phos­
phorylation of angiotensin I, an external substrate molecule for 
the activated EGFR. Figure 2 shows the incorporation of 
radiolabelled phosphate into angiotensin I, mediated by mem­
brane preparations of HER-7 cells. No significant differences 
were observed in receptor tyrosine kinase activity when com­
paring the dose-response curves of the superagonists with those 
of the wild-type growth factors (Figure 2A) and non-super­
agonists (Figure 2B).
Receptor routing induced by E G F / T G F - a  chimaeras
It has been shown by Ebner and Derynck [7] that human EGF 
and human TGF-a induce a different routing of the ligand- 
receptor complex after internalization. Figure 3(A) shows that 
incubation of HER-7 cells with wild-type human EGF and 
various chimaeras causes a strong decrease of cell-surface recep­
tors as a result of ligand-induced down-regulation, whereas E3T, 
E4T and T3E4T mimic human TGF-a in their ability to induce 
receptor recycling. The other mutants, which behave similarly to 
EGF, most likely target the receptor to degradation in the 
lysosomes.
To evaluate whether the differences observed for TGF-a and 
the superagonists are due to alterations in receptor recycling and 
not to differences in their ability to induce receptor internali­
zation, the same experiment was repeated in the presence of 
monensin, which is known to inhibit the recycling of trans-
currently not well understood, however, the maximum levels of membrane receptors [21], including the EGFR [22]. Figure 3(B) 
growth stimulation induced by some chimaeras appear to be shows that in the presence of monensin, the extent of ligand-
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Figure 1 Mitogenic stimulation of H E R -14  and HaCaT cells
The mitogenic stimulation of H E R - 1 4  (A) and HaCaT (B) cells was Investigated. The relative mitogenic activity ol h E G F  ( +  ), h T G F - a  (bold +  ), E3T ( • ) ,  T 3 E  ( O ) .  E 4 T  ( ▼ ) , T4 E ( V ) .  T6E ( O ) .  
E6T ( ♦  ), E3 T 4 E ( □ ) ,  T 3 E 4 T  ( ■ ) ,  T 4 E 6 T  (A) and E 4 T 6 E  ( A )  was assessed by measuring [:,H ]T d R  incorporation 24 h alter growth iactor addition. The stimulation is shown as a percentage
of the stimulation obtained with 1 0 %  N C S  or F C S . Radioactivity incorporation for H E R - 1 4  (A) cells In the presence of 1 0 %  N C S  was (3.11 ± 0 . 0 1 )  x  1 0J c.p.m,, whereas for HaCaT cells (B) 
radioactivity Incorporated In the presence of 1 0 %  FCS was (1.55 ± 0 . 1 6 )  x  1Q fi c.p.m. and in control colls, without growth Iactor addition, (35.8 +  3.6)% of this value. Data on H ER -14  cells were 
based on six independent experiments in triplicate, with the following mean and S .E .M .  values far the ECm (in ng/rnl): E G F ,  0,782 ± 0 . 0 2 4 ;  TGF-a, 0 .7 1 3  ± 0 , 0 4 2 ;  E3T, 0.142 ± 0 .0 0 3 ;  E4T, 
0 . 0 8 7 ± 0 . 0 1 7 ;  T 3 E 4 T , 0 . 1 0 0 ± 0 . 0 1 2 .  Data on HaCaT cells represent the mean and S .E .M  ol three independent experiments in triplicate, as follows (in ng/ml): EGF, 0 .1 5 0 ± 0 .0 1 2 ;  TGF-a,
0 .172 +  0 .0 1 2 ; E3 T, 0 .0 11  + 0 . 0 0 2 ;  E4T, 0.003 ±  0 .0 0 1 ;  T 3 E 4 T ,  0.015 ± 0 . 0 0 1 .
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Figure 2 Phosphorylation of angiotensin I by the human EG FR  present in membrane preperations of H E R -7  cells
Receptors were incubated for 60 min at room temperature with various concentrations of human E G F  ( + ) ,  human T G F - a  (bold + ) ,  E3 T ( # ) ,  T 3 E  ( O ) .  E 4 T  ( ▼ )  and T 4 E  ( V ) .  Angiotensin I and 
[ y - 32P ] A T P  were added and the mixture was incubated for 3 min at 30 ° C .  Incorporation of iWP into angiotensin I was subsequently determined as described in the Materials and methods section. 
In (A) the superagonists E 3 T  and E 4 T  are compared with wild-type E G F  and T G F - a ,  whereas in (B) the non-superagonists T 3 E  and T 4 E  are compared with the superagonist E4 T and wild-type 
E G F .  Data represent the means of duplicate experiments.
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Figure 3 ' 1 " ”  of the cell-surface EGF-receptor In H E R -7  fibroblasts
Confluent monolayers of both cells were treated with an excess of unlabelled h E G F  ( +  ), human TGF-a (bold + ) .  E3 T ( • ) ,  T 3 E  ( O ) .  E4 T ( ▼ ) ,  T 4 E  (V), T 6 E  (O). E6T ( ♦ ) ,  E3T4E ( □ ) ,  T 3 E 4 T  
( ■ ) ,  T 4 E 6 T  (A) and E 4 T 6 E  ( A )  lor 1 h at 4 “ C. Internalization was Induced by transferring the cells to 37 ° C  for the Indicated time periods, in the absence (A) or presence (B) of 0.3 m M  
mononsin, Cell-surface EGF-binding capacity of the cells was subsequently assayed by an incubation with 1 ng/ml murine , M I - E G F  for 1 h at 4 ° C ,  alter acid-stripping of receptor-bound ligand 
followed by a neutralization step with D M E M y H e p e s , pH 7 . 7 .  Data represent the means of three independent experiments In triplicate.
induced down-rcgulation of the receptors is very similar lor all 
ligands, indicating that under the experimental conditions tested, 
the rate of ligand-induced receptor internalization does not differ 
for superagonists and non-superagonists.
Mitogenic response of H E R - 5 6  cells expressing an internalization- 
impaired h E G F R / e r b B -2  chimera
To investigate whether differences in receptor routing induced by 
the various EG F/T G Fa chimaeras may account for the difference 
in mitogenic potency, superagonists and non-supcragonists were 
tested for their ability to stimulate the proliferation of quicscent 
HER-56 cells expressing a human EGFR/erbB-2 chimaera. This 
chimaeric receptor, which contains the human EGFR extra­
cellular domain and the transmembrane and intracellular domain 
oferbB-2, can be activated upon human EGF binding and is able 
to generate a potent mitogenic signal [23]. However, the ligand- 
induced internalization of this receptor is much slower and 
hardly any down-regulation of the receptor takes place [17]. The 
EG F/TG Fa chimaeras bound to this chimaeric rcecptor with an 
affinity similar to that of the wild-type growth factors (results not 
shown). Furthermore, Figure 4(A) shows that upon ligand 
binding the receptor remains located at the cell surface, ir­
respective of whether incubation was with wild-type or mutant 
growth factors, and that no significant ligand-induced receptor 
internalization occurs. When tested for their ability to induce a 
mitogenic response in HER-56 cells, chimaeric and wild-type 
growth factors were now almost equally potent (Figure 4B), This
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Figure 4 Down-regulation of the EGFR/erbB-2 chimaera In HER-56 cells (A) and mitogenic stimulation of HER 56-cells (B)
Down-regulalion of the chimaeric receptor in H E R -5 6  cells was measured as described in the legend of Figure 3 either in the absence (solid lines) or presence (hatched lines) of 0.3 m M monensin. 
Mitogenic stimulation of H E R -5 6  cells was assessed by measuring [3H ] T d R  incorporation 24 h after growth factor addition. Values are given as percentages of the stimulation obtained with 10 %  
N C S  [(5.38 +  0.15) x  1 05 c .p .m .] : h E G F  ( + ) ,  h T G F - a  (bold + ) ,  E3 T ( # ) ,  T 3 E  ( O ) ,  E 4 T  ( ▼ ) ,  T 4 E  ( V ) ,  E 3 T 4 E  ( □ ) ,  T 3 E 4 T  ( H ) .  Data In (A) represent the means of duplicate experiments, whereas 
the data in (B) represent the means of four independent experiments in triplicate. S . E . M .  is within 5 %  for all data points.
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Figure 5 pH-dependent inhibition of murine 1z5i-E G F  binding to H E R -7  cells
Fibroblasts were grown to confluence, after which a binding competition experiment was 
performed at room temperature in the presence ol 1 ng/ml murine l;'r’ l - E G F  and 100 ng/ml of 
human E G F  ( +  ), h T G F - a  (bold + ) ,  E 3 T  ( • ) ,  T 3 E  (O), E 4 T  (Y), T 4 E  ( V ) ,  T 6 E  ( O ) ,  EO T 
( ♦ ) ,  E3 T 4 E ( □ ) ,  T 3 E 4 T  ( ■ ) .  T 4 E 6 T  (A) and E 4 T 6 E  ( A )  for 2 h at room temperature in 
D M EM /B e s  at various pHs. The relative binding ability of the unlabelled ligands is given by 
( 1 0 0 - %  competition at variable p H ) / ( 1 0 0 - %  competition at pH 7.7).  Data represent ihe 
means ol three independent experiments in triplicate.
suggests that E3T, E4T and T3E4T are not superagonistic when 
compared with wild-type ligands in cells where the receptor is not 
internalized after activation.
EGF for binding to the human EGFR at different pH values. The 
data are presented relative to the binding ability at pH 7.7, which 
is similar for all growth factors tested [10], These results show that 
every ligand has its own characteristic pH dependence of binding, 
in which TG F-a and T3E4T rapidly lose their affinity for the 
receptor upon acidification, E3T and E4T show an intermediate 
binding property, whereas binding of EGF and all other ligands 
to the EGFR is much less pH-sensitive. These results show that 
the ability of the superagonists to induce receptor recycling, 
similar to TGF-a, is paralleled by an enhanced pl-I dependence 
of binding.
pH-dependent binding of E G F / T G F - a  chimaeras to the human 
E G F R
The ability of EGF to induce degradation of the human EGFR, 
and of TGF-a to induce receptor recycling, has been related to 
their difference in pH dependence of binding [7].
Figure 5 shows the ability of the various mutants, added at a 
fixed concentration of 100 ng/ml, to compete with murine [13r,I]- potent activity of TGF-a in some systems, although it is not clear
D IS C U S S IO N
In the present study we have investigated the mitogenic potential 
of ten previously characterized EG F/TG F-a chimaeras, and 
shown that three of them, E3T, E4T and T3E4T, behave as 
superagonists for the human EGF receptor. The observation 
that these superagonists can induce mitogenic activation at much 
lower levels of receptor occupation suggests that these ligands 
are either able to induce the EGFR to form a more active 
conformation, or that they may be able to activate individual 
receptor molecules for a longer period of time. The observation 
that tyrosine kinase activity of the activated receptor towards an 
external substrate molecule, such as angiotensin, is not different 
for the superagonists suggests that the first option is not likely, 
although more quantitative data will be required to exclude this 
possibility. The observation that no superagonistic activity is 
seen on the internalization-deficient human EGFR/erbB2 chim­
aera suggests that receptor internalization may be important for 
the observed enhanced mitogenicity. It has been established that, 
in the case of EGF, internalized receptor-ligand complexes are 
stable during gradual acidification in the endocytotic vesicles, 
resulting in degradation of both receptor and ligand in the 
lysosomes. In the case of TGF-a, the ligand dissociates from the 
internalized receptor-ligand complex as soon as the pH is lowered 
below 6.0, resulting in receptor recycling [8]. Ebner and Dcrynck 
[7] have suggested that this difference in routing of the EGFR 
after ligand-induced internalization could account for the more
864 A . E .  G . Lenferink and others
»h»t.
N o . of histidine
T a b le  1 Charge and histidine content of E G F / T G F -a  chimaeras a detailed comparison of the receptor internalization and routing
--------------- ------------------------------------------ kinetics induced by wild-type ligands and superagonists to be
made.
It is well known that the EG FR belongs to a multigene family, 
which also includes erbB2, 3 and 4. Recent studies have indicated 
that EGF-like growth factors can induce receptor dimerization, 
and that heterodimers, in particular with erbB2, are mitogenically 
very potent [31-33]. Preliminary studies using interleukin-3- 
dependent myeloid cells transfected with only erbB 1 suggest that 
the superagonistic activity of E3T, E4T and T3E4T is intrinsic to 
the human EGF receptor, and does not require receptor hetero- 
dimerization (A. E. G. Lenferink and Y. Yarden, unpublished 
work). Moreover, it is well known that the human EG FR  can 
occur in both a high- and a low-aflinity state [9], and it has been 
suggested that EGF-induced mitogenesis is primarily mediated 
by the so-called high-aflinity receptors [34,35], On cells extracted 
with Triton X-100, which are devoid o f so-called low-affinity 
reccptors, we observed however similar binding affinities of the 
wild-type ligands and the superagonists, indicating that super-
------- -—1 --------- ----------  ----------------------- 1 ■ agonists do not preferentially interact with such high-affinity
sites.
Many studies have been performed to elucidate the structure- 
why enhanced activity of T G F -a is then not a more general function relationship o f EG F and TG F-a with the final aim of
Growth factor I E P * residues'!*
Human F.GF 4.50 2
Human T G F - a 5.84 5
E 3 T 4 .7 0 4
T 3 E 5 . 7 7 3
E 4 T 4 .3 7 4
T 4 E 6.29 3
E 6 T 4.02 3
T O E 7.0 8 4
E 3 T 4 E 4.81 2
T 3 E 4 T 5.48 5
E4 TG E 5.21 3
T4 E O T 5 .1 3 4
t
Isoelectric point ( IE P )  calculated on the basis of the known p tf ,  values of individual amino 
a c id  side chains (also see [40 ]),
T o ta l hislklino content of E G F / T G F - a  chimaeras.
phenom enon.
E G F/
developing a receptor antagonist [1,25,36]. The present obser­
vations indicate that mutants with similar binding activities can
T G F - a  chimaeras with superagonistic activity induce receptor evoke different mitogenic responses, and from that point of view
recycling instead of receptor degradation, as observed similarly it can be concluded that it is possible to uncouple the process of
fo r T G F -a . In line with the model postulated by Ebner and ligand binding from the subsequent process of ligand-induced
D erynck  [7] there seems to be a correlation between receptor receptor activation, which is a prerequisite for the design of such
recycling and the pH dependence of binding of the mutants, since an antagonist. In agreement with this observation, recent studies
all three superagonists show clearly reduced binding at acidic pH indicate that EGF-like growth factors with low affinity for the
w hen compared with EGF, although, in particular, binding of EG FR can still have mitogenic activity very similar to that of
E 3T  and E4T seems less pH-sensitive than that of TGF-a. wild-type EGF [35,37-39]. The current study, however, is the first
F u therm ore , in the case of binding o f insulin and insulin-like to show that growth factors with a binding affinity similar to that
g ro w th  factors to Iheir receptors, a direct correlation has been of EGF can have enhanced mitogenic activity, 
observed  between pH dependence o f binding and receptor
recycling a f t e r  ligand-induced internalization [ 2 4 ] ,  In contrast W e  thank Dr.  T.  J .  Benraad and M r,  J .  J .  T .  M .  Heuvel (Department of Experimental
A  I ^  I. -  — i  1  > l  1  a « »  I I  t  j  I  A  a I I  k —  m 1 A l a i  •  l « 4
w ith the model of Ebner and Derynck [7], however, we observed 
no direct correlation between the overall isoelectric point (IEP) 
o f  the various E G F /T G F -a  chimaeras and their pH dependence 
o f  binding, This is illustrated by a comparison of Table I and 
F igure  3 which show that the .superagonists E3T and E4T have
I HP values similar to those o f EGF, but which induce 
recep to r recycling in a similar manner to TG F-a. Moreover, the 
ch im aeras H6T and T6E differ substantially in their iEPs, but 
show  almost identical pl-1 dependence of binding (see Figure 5). 
'fa b le  1 also shows that T G F-a and the superagonists have a 
relatively high histidine content, which is the amino acid with the 
pA.'„ value of its side chain closest to the pH range used in Figure 
5. F urther research will be required to establish a causal 
relationship between pH dependence o f binding and the presence 
o f  specific histidine residues [25].
T here  is increasing evidence that tyrosine kinase receptors can 
still be active in generating second messengers after ligand- 
induced internalization [26,27], This suggests that, in the case of 
F G F , receptors can have a long signalling period, both initally at 
the cell surface and during the course of internalization [28], but 
because of' lysosomal degradation, each receptor can be used 
only once [29,30]. In the case of TG F-a, signalling is restricted to 
the cell surface but receptors can be used more than once as a 
result o f recycling. Under most experimental conditions these 
two signalling mechanisms seem to converge to induce similar 
m itogenic responses. If the hypothesis that the intensity of 
m itogenic stimulation through the EGF'R is limited by ligand- 
intlueed receptor internalization is correct, this would encourage
and Chem ical En d o c rin o lo g y, University Hospital St. Radboud, The Netherlands) for 
tha generous supply of m urine 125I - E G F .  The current studies were carried out with 
financial support from the D u tc h  Cancer Society ( K W F ) .
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